Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a $22.00 price objective on the stock.

Several other analysts have also issued reports on the company. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. Finally, Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price on the stock. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Stock Up 0.9 %

Shares of NASDAQ YMAB opened at $6.39 on Monday. The stock’s 50 day moving average price is $9.97 and its 200-day moving average price is $12.04. The company has a market capitalization of $286.20 million, a PE ratio of -11.83 and a beta of 0.69. Y-mAbs Therapeutics has a twelve month low of $6.01 and a twelve month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the business posted ($0.18) earnings per share. As a group, research analysts expect that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after acquiring an additional 3,416 shares during the last quarter. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics during the third quarter valued at approximately $133,000. SG Americas Securities LLC bought a new position in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $178,000. Finally, Empire Financial Management Company LLC bought a new position in Y-mAbs Therapeutics in the third quarter valued at about $210,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.